St. Gallen International Breast Cancer Conference | Conference

Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer

March 19th 2017

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Neoadjuvant Therapy Fundamental in TNBC and HER2+ Breast Cancer

March 19th 2017

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

Age, Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer

March 18th 2017

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

Expert Examines Clues to Deploying Immunotherapy in Breast Cancer

March 18th 2017

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

Big Data May Guide Future Treatment Decisions

March 17th 2017

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

CDK4/6 Inhibitors Changing Practice in Advanced Breast Cancer

March 17th 2017

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Expert Discusses Promise of Immunotherapy in TNBC

March 17th 2017

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer

March 17th 2017

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

Dr. Piccart on the Importance of De-Escalation in Early Breast Cancer

March 17th 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer

March 17th 2017

Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.

Ribociclib Response Unaffected by Prior Treatment

March 17th 2017

Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.

Combinations Show Promise in Overcoming Resistance to HER2-Targeting Therapy

March 16th 2017

C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

March 16th 2017

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

March 16th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.